{
    "nctId": "NCT00323063",
    "briefTitle": "Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer",
    "officialTitle": "Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 49,
    "primaryOutcomeMeasure": "Time to Progression",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Locally advanced or metastatic disease\n  * Disease progression after at least 1 prior chemotherapy regimen for metastatic disease\n\n    * No more than 2 prior chemotherapy regimens for metastatic disease (prior neoadjuvant or adjuvant treatment will not be included in determining the number of prior chemotherapy regimens)\n* Measurable disease\n* No known symptomatic or untreated brain metastases or carcinomatous meningitis\n\n  * Previously treated and clinically stable brain metastases allowed provided patient has been off steroids for \\> 7 days\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Male or female\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Life expectancy \u2265 3 months\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* AST or ALT \u2264 2.5 times ULN\n* Creatinine \u2264 1.5 times ULN OR creatinine clearance \u2265 60 mL/min\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 3 months after completion of study therapy\n* Able to swallow oral medication\n* No coexisting medical condition that would preclude study compliance\n* No uncontrolled illness, including any of the following:\n\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia requiring therapy\n  * Myocardial infarction within the past 6 months\n  * Active infection\n* No New York Heart Association class III-IV cardiac disease\n* No history of allergic reaction attributed to compounds of similar chemical or biologic composition to gemcitabine hydrochloride and/or imatinib mesylate\n* No other primary malignancies within the past 5 years except for carcinoma in situ of the cervix or nonmelanoma skin cancer\n* No known chronic liver disease (i.e., chronic active hepatitis or cirrhosis)\n* No known HIV infection\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Recovered from all prior therapy\n* More than 2 weeks since prior surgery\n* At least 2 weeks since prior hormonal therapy\n* At least 2 weeks since prior trastuzumab (Herceptin\u00ae)\n* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n* At least 3 weeks since prior anti-vascular endothelial growth factor therapy\n* More than 28 days since prior investigational agents\n* At least 3 weeks since prior radiotherapy\n\n  * Must have evidence of \u2265 1 measurable target lesion outside the irradiated fields OR radiologically confirmed disease progression within the irradiated fields after completion of radiotherapy\n* No prior imatinib mesylate for metastatic disease\n* No prior gemcitabine hydrochloride for metastatic disease\n* More than 6 months since prior adjuvant gemcitabine hydrochloride\n* No other concurrent investigational or commercial agents\n* No concurrent therapeutic anticoagulation with warfarin (e.g., Coumadin\u00ae or Coumadine\u00ae)\n\n  * Concurrent heparin or low-molecular weight heparin (e.g., Lovenox\u00ae) for therapeutic anticoagulation allowed\n  * Concurrent prophylactic warfarin therapy (e.g., mini-dose Coumadin\u00ae \u2264 1 mg daily) to maintain catheter patency allowed\n* No concurrent routine chronic systemic corticosteroids\n* No concurrent medications that would preclude study compliance",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}